Top

Published in:

Open Access 01-12-2018 | Review

White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes

Authors: Sara E. Nasrabady, Batool Rizvi, James E. Goldman, Adam M. Brickman

Published in: Acta Neuropathologica Communications | Issue 1/2018

Abstract

Alzheimer’s disease (AD) is conceptualized as a progressive consequence of two hallmark pathological changes in grey matter: extracellular amyloid plaques and neurofibrillary tangles. However, over the past several years, neuroimaging studies have implicated micro- and macrostructural abnormalities in white matter in the risk and progression of AD, suggesting that in addition to the neuronal pathology characteristic of the disease, white matter degeneration and demyelination may be also important pathophysiological features. Here we review the evidence for white matter abnormalities in AD with a focus on myelin and oligodendrocytes, the only source of myelination in the central nervous system, and discuss the relationship between white matter changes and the hallmarks of Alzheimer’s disease. We review several mechanisms such as ischemia, oxidative stress, excitotoxicity, iron overload, Aβ toxicity and tauopathy, which could affect oligodendrocytes. We conclude that white matter abnormalities, and in particular myelin and oligodendrocytes, could be mechanistically important in AD pathology and could be potential treatment targets.

Al-Mashhadi S, Simpson JE, Heath PR, Dickman M, Forster G, Matthews FE, Brayne C, Ince PG, Wharton SB (2015) Oxidative glial cell damage associated with white matter lesions in the aging human brain. Brain pathology (Zurich, Switzerland) 25:565–574. https://doi.org/10.1111/bpa.12216 CrossRef

Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ (1998) Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 18:6241–6253PubMed

Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J, Arvin KL, Holtzman DM (2002) Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 22:455–463PubMed

Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663–672. https://doi.org/10.1038/nrn2194 CrossRefPubMed

Bartzokis G (2011) Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 32: 1341-1371 Doi 0.1016/j.Neurobiolaging.2009.08.007

Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J (2003) White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol 60:393–398CrossRefPubMed

Bartzokis G, Lu PH, Mintz J (2007) Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement 3:122–125. https://doi.org/10.1016/j.jalz.2007.01.019 CrossRefPubMedPubMedCentral

Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL (2004) Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 25:843–851. https://doi.org/10.1016/j.neurobiolaging.2003.09.005 CrossRefPubMed

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TMet al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367: 795–804 Doi https://doi.org/10.1056/NEJMoa1202753

10.

Baumann N, Pham-Dinh D (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81:871–927CrossRefPubMed

11.

Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, Gotz M, Dimou L (2013) Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61:273–286. https://doi.org/10.1002/glia.22432 CrossRefPubMed

12.

Bender AR, Volkle MC, Raz N (2016) Differential aging of cerebral white matter in middle-aged and older adults: a seven-year follow-up. NeuroImage 125:74–83. https://doi.org/10.1016/j.neuroimage.2015.10.030 CrossRefPubMed

13.

Benitez A, Fieremans E, Jensen JH, Falangola MF, Tabesh A, Ferris SH, Helpern JA (2014) White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease. NeuroImage Clinical 4:64–71. https://doi.org/10.1016/j.nicl.2013.11.001 CrossRefPubMed

14.

Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837–1844. https://doi.org/10.1212/01.wnl.0000219668.47116.e6 CrossRefPubMed

15.

Bergles DE, Roberts JD, Somogyi P, Jahr CE (2000) Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 405:187–191. https://doi.org/10.1038/35012083 CrossRefPubMed

16.

Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45:675–688. https://doi.org/10.1016/j.neuron.2005.01.040 CrossRefPubMed

17.

Braak H, Braak E (1996) Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 92:197–201CrossRefPubMed

18.

Brickman AM (2013) Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep 13:415. https://doi.org/10.1007/s11910-013-0415-7 CrossRefPubMed

19.

Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R (2012) Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 69:1621–1627. https://doi.org/10.1001/archneurol.2012.1527 CrossRefPubMedPubMedCentral

20.

Brickman AM, Schupf N, Manly JJ, Stern Y, Luchsinger JA, Provenzano FA, Narkhede A, Razlighi Q, Collins-Praino L, Artero S et al (2014) APOE epsilon4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role? Alzheimers Dement 10:619–629. https://doi.org/10.1016/j.jalz.2014.07.155 CrossRefPubMedPubMedCentral

21.

Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB, Griffith EY, Provenzano FA, Schupf N, Manly JJ, Stern Y et al (2015) Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging 36:27–32. https://doi.org/10.1016/j.neurobiolaging.2014.07.019 CrossRefPubMed

22.

Brody BA, Kinney HC, Kloman AS, Gilles FH (1987) Sequence of central nervous system myelination in human infancy. I. An autopsy study of myelination. J Neuropathol Exp Neurol 46:283–301CrossRefPubMed

23.

Brown WR, Thore CR (2011) Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 37:56–74. https://doi.org/10.1111/j.1365-2990.2010.01139.x CrossRefPubMedPubMedCentral

24.

Chittajallu R, Aguirre A, Gallo V (2004) NG2-positive cells in the mouse white and grey matter display distinct physiological properties. J Physiol 561:109–122. https://doi.org/10.1113/jphysiol.2004.074252 CrossRefPubMedPubMedCentral

25.

Collins-Praino LE, Francis YI, Griffith EY, Wiegman AF, Urbach J, Lawton A, Honig LS, Cortes E, Vonsattel JP, Canoll PD et al (2014) Soluble amyloid beta levels are elevated in the white matter of Alzheimer’s patients, independent of cortical plaque severity. Acta Neuropathol Commun 2:83. https://doi.org/10.1186/s40478-014-0083-010.1186/preaccept-3091772881321882 PubMedPubMedCentral

26.

De Leeuw FE, Barkhof F, Scheltens P (2004) Alzheimer’s disease--one clinical syndrome, two radiological expressions: a study on blood pressure. J Neurol Neurosurg Psychiatry 75:1270–1274. https://doi.org/10.1136/jnnp.2003.030189 CrossRefPubMedPubMedCentral

27.

Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE (2004) Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci U S A 101:7751–7756. https://doi.org/10.1073/pnas.0307850101 CrossRefPubMedPubMedCentral

28.

Desai MK, Guercio BJ, Narrow WC, Bowers WJ (2011) An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia 59:627–640. https://doi.org/10.1002/glia.21131 CrossRefPubMedPubMedCentral

29.

Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ (2010) Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 177:1422–1435. https://doi.org/10.2353/ajpath.2010.100087 CrossRefPubMedPubMedCentral

30.

Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ (2009) Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57:54–65. https://doi.org/10.1002/glia.20734 CrossRefPubMedPubMedCentral

31.

Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC (2013) Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 81:977–983. https://doi.org/10.1212/WNL.0b013e3182a43e45 CrossRefPubMedPubMedCentral

32.

Fields RD (2015) A new mechanism of nervous system plasticity: activity-dependent myelination. Nat Rev Neurosci 16:756–767. https://doi.org/10.1038/nrn4023 CrossRefPubMed

33.

Fischer FU, Wolf D, Scheurich A, Fellgiebel A (2015) Altered whole-brain white matter networks in preclinical Alzheimer's disease. NeuroImage Clinical 8:660–666. https://doi.org/10.1016/j.nicl.2015.06.007 CrossRefPubMedPubMedCentral

34.

French HM, Reid M, Mamontov P, Simmons RA, Grinspan JB (2009) Oxidative stress disrupts oligodendrocyte maturation. J Neurosci Res 87:3076–3087. https://doi.org/10.1002/jnr.22139 CrossRefPubMedPubMedCentral

35.

Gagyi E, Kormos B, Castellanos KJ, Valyi-Nagy K, Korneff D, LoPresti P, Woltjer R, Valyi-Nagy T (2012) Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia. Brain pathology (Zurich, Switzerland) 22:803–810. https://doi.org/10.1111/j.1750-3639.2012.00595.x CrossRef

36.

Gao J, Cheung RT, Lee TM, Chu LW, Chan YS, Mak HK, Zhang JX, Qiu D, Fung G, Cheung C (2011) Possible retrogenesis observed with fiber tracking: an anteroposterior pattern of white matter disintegrity in normal aging and Alzheimer’s disease. Journal of Alzheimer’s disease : JAD 26:47–58. https://doi.org/10.3233/jad-2011-101788 PubMed

37.

Gogate N, Verma L, Zhou JM, Milward E, Rusten R, O'Connor M, Kufta C, Kim J, Hudson L, Dubois-Dalcq M (1994) Plasticity in the adult human oligodendrocyte lineage. The Journal of neuroscience : the official journal of the Society for Neuroscience 14:4571–4587

38.

Gouw AA, Seewann A, Vrenken H, van der Flier WM, Rozemuller JM, Barkhof F, Scheltens P, Geurts JJ (2008) Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain : a journal of neurology 131:3286–3298. https://doi.org/10.1093/brain/awn265 CrossRef

39.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JWet al (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (London, England) 372: 216-223 Doi https://doi.org/10.1016/s0140-6736(08)61075-2

40.

Horiuchi M, Maezawa I, Itoh A, Wakayama K, Jin LW, Itoh T, Decarli C (2012) Amyloid beta1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol Aging 33:499–509. https://doi.org/10.1016/j.neurobiolaging.2010.05.007 CrossRefPubMed

41.

Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG (2003) Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 14:1429–1433. https://doi.org/10.1097/01.wnr.0000086097.47480.a0 CrossRefPubMed

42.

Jorgensen AM, Marner L, Pakkenberg B (2008) No change in total length of white matter fibers in Alzheimer's disease. Neuroscience 157:878–883. https://doi.org/10.1016/j.neuroscience.2008.06.075 CrossRefPubMed

43.

Juurlink BH, Thorburne SK, Hertz L (1998) Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 22:371–378CrossRefPubMed

44.

Kapfhammer JP, Schwab ME (1994) Inverse patterns of myelination and GAP-43 expression in the adult CNS: neurite growth inhibitors as regulators of neuronal plasticity? J Comp Neurol 340:194–206. https://doi.org/10.1002/cne.903400206 CrossRefPubMed

45.

Kelleher RJ 3rd, Shen J (2017) Presenilin-1 mutations and Alzheimer's disease. Proc Natl Acad Sci U S A 114:629–631. https://doi.org/10.1073/pnas.1619574114 CrossRefPubMedPubMedCentral

46.

Kukley M, Capetillo-Zarate E, Dietrich D (2007) Vesicular glutamate release from axons in white matter. Nat Neurosci 10:311–320. https://doi.org/10.1038/nn1850 CrossRefPubMed

47.

Lebel C, Beaulieu C (2011) Longitudinal development of human brain wiring continues from childhood into adulthood. J Neurosci 31:10937–10947. https://doi.org/10.1523/jneurosci.5302-10.2011 CrossRefPubMed

48.

Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164:123–131. https://doi.org/10.1083/jcb.200307017 CrossRefPubMedPubMedCentral

49.

Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC et al (2016) White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol 79:929–939. https://doi.org/10.1002/ana.24647 CrossRefPubMedPubMedCentral

50.

Marner L, Nyengaard JR, Tang Y, Pakkenberg B (2003) Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 462:144–152. https://doi.org/10.1002/cne.10714 CrossRefPubMed

51.

Marques S, Zeisel A, Codeluppi S, van Bruggen D, Mendanha Falcao A, Xiao L, Li H, Haring M, Hochgerner H, Romanov RAet al (2016) Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science (New York, NY) 352: 1326-1329 Doi https://doi.org/10.1126/science.aaf6463

52.

Mason JL, Langaman C, Morell P, Suzuki K, Matsushima GK (2001) Episodic demyelination and subsequent remyelination within the murine central nervous system: changes in axonal calibre. Neuropathol Appl Neurobiol 27:50–58CrossRefPubMed

53.

Matute C (2010) Calcium dyshomeostasis in white matter pathology. Cell Calcium 47:150–157. https://doi.org/10.1016/j.ceca.2009.12.004 CrossRefPubMed

54.

Matute C (2006) Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol Med 12:289–292. https://doi.org/10.1016/j.molmed.2006.05.004 CrossRefPubMed

55.

Matute C, Alberdi E, Domercq M, Sanchez-Gomez MV, Perez-Samartin A, Rodriguez-Antiguedad A, Perez-Cerda F (2007) Excitotoxic damage to white matter. J Anat 210:693–702. https://doi.org/10.1111/j.1469-7580.2007.00733.x CrossRefPubMedPubMedCentral

56.

McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, Beverley JR, Taylor JP, Thomas AJ, O’Brien JT et al (2015) Cortical tau load is associated with white matter hyperintensities. Acta neuropathologica communications 3:60. https://doi.org/10.1186/s40478-015-0240-0 CrossRefPubMedPubMedCentral

57.

McAleese KE, Walker L, Graham S, Moya ELJ, Johnson M, Erskine D, Colloby SJ, Dey M, Martin-Ruiz C, Taylor JP et al (2017) Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta neuropathologica. https://doi.org/10.1007/s00401-017-1738-2

58.

McKenzie IA, Ohayon D, Li H, de Faria JP, Emery B, Tohyama K, Richardson WD (2014) Motor skill learning requires active central myelination. Science (New York, NY) 346:318–322. https://doi.org/10.1126/science.1254960 CrossRef

59.

Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A (2006) Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26:7907–7918. https://doi.org/10.1523/jneurosci.1299-06.2006 CrossRefPubMed

60.

Pak K, Chan SL, Mattson MP (2003) Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice. NeuroMolecular Med 3:53–64. https://doi.org/10.1385/nmm:3:1:53 CrossRefPubMed

61.

Pantoni L, Garcia JH (1997) Cognitive impairment and cellular/vascular changes in the cerebral white matter. Ann N Y Acad Sci 826:92–102CrossRefPubMed

62.

Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW et al (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30:1026–1036. https://doi.org/10.1016/j.neurobiolaging.2009.04.002 CrossRefPubMedPubMedCentral

63.

Prins ND, Scheltens P (2015) White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 11:157–165. https://doi.org/10.1038/nrneurol.2015.10 CrossRefPubMed

64.

Raz N, Yang Y, Dahle CL, Land S (2012) Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta 1822:361–369. https://doi.org/10.1016/j.bbadis.2011.08.007 CrossRefPubMed

65.

Reisberg B, Franssen EH, Hasan SM, Monteiro I, Boksay I, Souren LE, Kenowsky S, Auer SR, Elahi S, Kluger A (1999) Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes. Eur Arch Psychiatry Clin Neurosci 249(Suppl 3):28–36CrossRefPubMed

66.

Reisberg B, Franssen EH, Souren LE, Auer SR, Akram I, Kenowsky S (2002) Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: management and treatment import. Am J Alzheimers Dis Other Demen 17:202–212. https://doi.org/10.1177/153331750201700411 CrossRefPubMed

67.

Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, al WD (2002) Increased a beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41:11080–11090CrossRefPubMed

68.

Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W (1995) Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 45:883–888CrossRefPubMed

69.

Schuff N, Matsumoto S, Kmiecik J, Studholme C, Du A, Ezekiel F, Miller BL, Kramer JH, Jagust WJ, Chui HC et al (2009) Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 5:454–462. https://doi.org/10.1016/j.jalz.2009.04.1233 CrossRefPubMedPubMedCentral

70.

Schwab ME (1990) Myelin-associated inhibitors of neurite growth and regeneration in the CNS. Trends Neurosci 13:452–456CrossRefPubMed

71.

Scott JA, Braskie MN, Tosun D, Thompson PM, Weiner M, DeCarli C, Carmichael OT (2015) Cerebral amyloid and hypertension are independently associated with white matter lesions in elderly. Front Aging Neurosci 7:221. https://doi.org/10.3389/fnagi.2015.00221 CrossRefPubMedPubMedCentral

72.

Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17:1060–1065. https://doi.org/10.1038/nm.2460 CrossRefPubMed

73.

Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210 CrossRefPubMedPubMedCentral

74.

Simpson JE, Fernando MS, Clark L, Ince PG, Matthews F, Forster G, O'Brien JT, Barber R, Kalaria RN, Brayne C et al (2007) White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol Appl Neurobiol 33:410–419. https://doi.org/10.1111/j.1365-2990.2007.00828.x CrossRefPubMed

75.

Sims R, Hollingworth P, Moskvina V, Dowzell K, O'Donovan MC, Powell J, Lovestone S, Brayne C, Rubinsztein D, Owen MJ et al (2009) Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease. Neurosci Lett 461:54–59. https://doi.org/10.1016/j.neulet.2009.05.051 CrossRefPubMed

76.

Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY, Frank LR, Salmon DP, Bondi MW (2009) Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. NeuroImage 45:10–16. https://doi.org/10.1016/j.neuroimage.2008.11.027 CrossRefPubMed

77.

Thorburne SK, Juurlink BH (1996) Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 67:1014–1022CrossRefPubMed

78.

Tosto G, Zimmerman ME, Carmichael OT, Brickman AM (2014) Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA neurology 71:872–877. https://doi.org/10.1001/jamaneurol.2014.667 CrossRefPubMedPubMedCentral

79.

Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM (2015) The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement 11:1510–1519. https://doi.org/10.1016/j.jalz.2015.05.014 CrossRefPubMedPubMedCentral

80.

Tsai HH, Niu J, Munji R, Davalos D, Chang J, Zhang H, Tien AC, Kuo CJ, Chan JR, Daneman R et al (2016) Oligodendrocyte precursors migrate along vasculature in the developing nervous system. Science (New York, NY) 351:379–384. https://doi.org/10.1126/science.aad3839 CrossRef

81.

Tse KH, Herrup K (2017) DNA damage in the oligodendrocyte lineage and its role in brain aging. Mech Ageing Dev 161:37–50. https://doi.org/10.1016/j.mad.2016.05.006 CrossRefPubMed

82.

Tse KH, Herrup K (2017) Re-imagining Alzheimer’s disease - the diminishing importance of amyloid and a glimpse of what lies ahead. J neurochemistry. https://doi.org/10.1111/jnc.14079

83.

Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 2’,3’-cyclic nucleotide-3’-phosphodiesterase in down syndrome and Alzheimer’s disease. Neurobiol Aging 22:547–553CrossRefPubMed

84.

Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY (2001) Amyloid-beta peptides are cytotoxic to oligodendrocytes. The journal of neuroscience : the official journal of the Society for Neuroscience 21: Rc118

85.

Yuen TJ, Silbereis JC, Griveau A, Chang SM, Daneman R, Fancy SP, Zahed H, Maltepe E, Rowitch DH (2014) Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell 158:383–396. https://doi.org/10.1016/j.cell.2014.04.052 CrossRefPubMedPubMedCentral

86.

Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV (2015) Establishment and dysfunction of the blood-brain barrier. Cell 163:1064–1078. https://doi.org/10.1016/j.cell.2015.10.067 CrossRefPubMedPubMedCentral

Title: White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes
Authors: Sara E. Nasrabady
Batool Rizvi
James E. Goldman
Adam M. Brickman
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2018
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-018-0515-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Skeletal myopathy in Pompe disease: a failure of satellite cell activation?

Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease

Alterations in mitochondria-endoplasmic reticulum connectivity in human brain biopsies from idiopathic normal pressure hydrocephalus patients

Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer’s disease patients

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease